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Abstract
Title:

Malignant Hyperthermia Precautions in the Pediatric Patient

Background: An 8-year-old patient presented for a tonsillectomy and adenoidectomy for acute
pharyngitis and recurrent strep tonsillitis. The patient had a family history
significant for malignant hyperthermia (MH), a hypermetabolic skeletal muscle
disorder that is triggered by commonly used anesthetic gases and succinylcholine.
If not prepared for, recognized, or swiftly diagnosed, this hypermetabolic reaction
can be fatal for the pediatric patient.
Purpose:

To review the genetic component of this inherited disorder, as well as the current
recommendations for preparation, treatment, and anesthetic management in
pediatric patients with a personal or family history of MH.

Process:

A systematic literature review was completed utilizing the University of North
Dakota’s Harley E. French Library. The databases used included CINAHL and
PubMed. The search was carried out with the use of controlled vocabulary and
limits on the publications to include recent and efficacious data. The information
gathered is presented to provide evidence-based recommendations for the care of
the pediatric patient presenting for a general anesthetic that has a personal or
family history of MH.

Results:

Multiple case reports, meta-analyses, and pieces of clinical evidence were
reviewed and data gathered for use in the development of a recommendation for
the preparation and care of the MH susceptible pediatric patient. Evidence-based
preparatory steps are outlined, as well as recognizable manifestations that may be
seen. The use of total intravenous anesthesia (TIVA) through the administration
of propofol or dexmedetomidine is outlined. Pediatric patients with MH
susceptibility should be discharged only after a minimum of a one hour stay in the
post anesthesia care unit (PACU) and satisfying the facility-specific
predetermined discharge criteria.

Implications: Due to the potential for end-organ complications and fatality, the appropriate
precautions should be taken prior to admitting an MH susceptible pediatric patient
to the operating room for a safe, nontriggering general anesthetic. In addition to
preparatory steps that can be taken to prepare the operative suite, a nontriggering
general anesthetic with appropriate monitoring should be implemented. Once the
surgery is completed, the pediatric patient should be monitored in the PACU for a
minimum of one hour before discharge, assuming the patient meets the
appropriate criteria.
Keywords:

Malignant Hyperthermia, Pediatric, Anesthesia, Genetics, RYR1 Mutation,
Dantrolene, TIVA
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Malignant Hyperthermia Precautions in the Pediatric Population
Background
Malignant hyperthermia (MH) is an “uncommon, life-threatening, hypermetabolic
disorder of skeletal muscle” (Nagelhout & Elisha, 2018, p. 773). The first reported MH event
occurred in 1960 as witnessed by Denborough and Lovell after a patient, concerned about
receiving anesthesia, reported that ten of his family members had died while undergoing a
general anesthetic (Hopkins, Gupta, & Bilmen, 2018). This initial occurrence of the reaction
brings to light the importance of genetics in the recognition and diagnosis of MH, as well as the
potential implications for pediatric patients that present for general anesthesia.
The incidence of MH is not exactly known, but is estimated to be a complication in the
range of 1 in 3,000 to 1 in 50,000 general anesthetics (Nagelhout & Elisha, 2018). The incidence
of an MH crisis was 1 in 62,000 anesthetics when triggering agents were not used and increased
to 1 in 4,500 anesthetics when triggering agents were administered during general anesthesia
(Miller, 2015). MH is thought to affect males more than females, and is also more common in
children under the age of 15. In addition, the incidence of MH is higher in the French,
Scandinavian, and Japanese populations, though every ethnicity may be affected (Mullins, 2017).
Due to the genetic component of the disorder, clusters of MH susceptible patients exist in the
states of Wisconsin, Nebraska, West Virginia, and Michigan in the United States (Mullins,
2017). The prevalence of MH in relatives that are known carriers of an MH mutation is 1 in
2,000 (Miller, 2015).
The mortality of MH was nearly 60% when it was first discovered, and because of the
development of protocols and the introduction of dantrolene into practice, the mortality rate has
been reduced to less than 5% (Miller, 2015). MH reactions that are not treated promptly can lead
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to many end-organ complications. Untreated MH reactions are fatal, illuminating the need for
appropriate preparation, swift recognition, and prompt treatment of the reaction by anesthesia
professionals (Hopkins et al., 2018).
In addition to the potential for fatality, another alarming statistic is the fact that the
pediatric patient population accounts for 52.1% of all MH reactions (Miller, 2015). Pediatric
implications of having a personal or family history of MH susceptibility are related to all phases
of anesthesia care. It is vital that anesthesia professionals understand preoperative,
intraoperative, and postoperative management of pediatric patients who are at risk for MH to
prevent a potentially fatal occurrence in the operating room. Appropriate anesthetic plans should
be prescribed for the pediatric patient that may be MH susceptible, and preparatory steps should
be taken to ensure that the child’s anesthetic course proceeds smoothly. The presented case
describes an appropriate anesthetic plan for the management of an MH susceptible pediatric
patient, followed by a literature review that describes the considerations that should be called to
mind when caring for an MH susceptible child.
Case Report
An 8-year-old male presented for a tonsillectomy and adenoidectomy for acute
pharyngitis and recurrent episodes of strep tonsillitis. The patient was categorized as an
American Society of Anesthesiologists classification score of 1. The patient’s past medical
history included Lyme disease and a left arm fracture. The child had not undergone any prior
surgical procedures. The patient was not taking any prescribed medications with the exception of
amoxicillin/clavulanic acid (Augmentin) for the treatment of his recent tonsillitis infection. A
preoperative assessment revealed vital signs and a review of systems that were all within normal
limits for his age. The patient weighed 37.8 kg and was 142.24 cm tall. Laboratory studies were
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not indicated, and therefore they were not completed prior to the scheduled surgical procedure.
The patient was determined to be a Mallampati airway class I with a full range of motion in his
neck and a thyromental distance greater than three fingerbreadths. The patient’s family medical
history was pertinent for MH reactions related to general anesthesia in both his mother and
grandmother.
Because it was known that this child was potentially MH susceptible, preparatory steps
were taken to ensure that the operating room environment would be safe for the child to proceed
with general anesthesia. The anesthetic gas vaporizers were removed from the anesthesia
machine, a new pediatric-sized breathing bag and circuit were attached, a fresh CO2 absorbent
was applied, and charcoal filters were placed on the inspiratory and expiratory limbs of the
machine. The anesthesia machine was then flushed for 90 seconds to purge any residual volatile
anesthetic gas from the machine per the recommendations of the manufacturer.
The patient received oral midazolam 20 mg in the preoperative area. Upon arrival to the
operating room, N2O 70% and O2 30% were administered to the child via facemask to allow for
the placement of a 24-gauge intravenous line. The patient was then given lidocaine 30 mg,
propofol 100 mg, and fentanyl 20 mcg intravenously for the induction of general anesthesia.
After an appropriate anesthetic depth was achieved, the patient’s trachea was easily intubated
with a 5.0 mm oral RAE endotracheal tube in one attempt using a Miller 2 blade. A leak of less
than 20 cm H2O was noted. The patient’s EtCO2 was noted to be present and bilateral breath
sounds were confirmed to assess proper endotracheal tube placement. The patient was then
placed on the ventilator in a pressure support mode to achieve a tidal volume of 4-6 mL/kg. The
patient’s initial temperature was 37°C, and all other vital signs remained stable through the
induction of general anesthesia.
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The patient’s anesthetic depth was maintained with a propofol infusion that was infused
at a rate of 140 mcg/kg/min for the duration of the surgical procedure. An additional dose of
fentanyl 10 mcg was administered during the procedure, for a total dose of 30 mcg of fentanyl.
Antiemetics, including ondansetron 4 mg and dexamethasone 8 mg, were given intravenously. A
total of 150 mL of lactated ringer’s solution was infused during the case. The patient’s vital signs
and EtCO2 remained within normal limits throughout the surgical procedure. The estimated
blood loss for this case was 1 mL. The patient was extubated when awake and able to sustain
adequate tidal volumes. The patient was subsequently transferred to the post anesthesia care unit
(PACU) in a drowsy state with 6 L of O2 flowing through a simple facemask. The patient’s
temporal temperature immediately after arriving in the PACU was 36.6°C. Through a chart
review, the patient was noted to be monitored in PACU for one hour before being moved to the
facility’s discharge unit. There he was monitored for one additional hour prior to being
discharged home. The patient’s temperature remained stable throughout the postoperative course
until he was discharged upon reaching the appropriate criteria. The patient had no apparent
complications from his general anesthetic, including the lack of postoperative nausea and
vomiting, recall, and uncontrolled pain.
Literature Search Methods
Databases
A search in the CINAHL database was completed to obtain literature related to nursing
and allied health to determine appropriate recognition, interventions, and management of MH in
the pediatric patient population (Stillwell, Fineout-Overholt, Mazurek & Williamson, 2010). The
text heading search terms of “malignant hyperthermia,” “pediatric,” “genetics,” “TIVA,” and
“anesthesia,” were utilized for this literature search. The limits of “peer reviewed,” “randomized
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controlled trials,” “meta-analysis,” and a date range between 2008 and 2018 were first used to
obtain the most relevant and recent data related to the identified topic. With these limits, there
were no relevant results yielded. The search was then repeated using only the limits of “peer
reviewed,” “human,” and the date range for the past 10 years. After the searches were completed,
there were fourteen relevant articles found for a review of literature to be completed. Case
reports were excluded, leaving nine of the fourteen articles to be utilized for a literature review to
maintain a high level of evidence for the articles included.
A search in the PubMed database was then completed to include literature relevant to
medical and life sciences pertinent to MH in pediatric patients (Stillwell et al., 2010). MeSH
terms were used when available in addition to the text heading search terms which included
“malignant hyperthermia,” “pediatric,” “genetics,” and “anesthesia.” The search yielded ten
articles of relevance for the identified topic. After duplicate articles were removed, four of these
articles were found to have a high level of evidence and they were all included in the literature
review that was completed. Again, to ensure the most recent and accurate data was obtained, the
limiting factors of “peer-reviewed” and “human” with the date range of the past ten years were
utilized.
Once the search in the databases listed above was completed, the reference sections of the
relevant articles obtained were reviewed to identify further research that could be of use for the
described topic. There was a significant overlap in the review of cited references with that of the
articles of relevance obtained from the initial literature search, which was promising for the
utility of the literature. A search in the SCOPUS database was completed without finding any
additional articles of relevance to be added to the review of literature. A brief literature search
within Google Scholar was then completed to round out the collection of data. This search
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yielded three relevant article results, in addition to the use of the Malignant Hyperthermia
Association of the United States (MHAUS) website. Overall, there is a high level of evidence
that was gathered to present evidence-based recommendations in the recognition, treatment, and
anesthetic management of MH susceptible pediatric patients.
Discussion
Pathophysiology
In an individual that does not have a history of MH or of being MH susceptible, the
neurotransmitter acetylcholine initiates an action potential that moves along the sarcolemma of a
muscle fiber to ultimately affect the RYR1 receptor. Once an action potential reaches the RYR1
receptor, a channel is opened and calcium is released from the sarcoplasmic reticulum (SR) into
the cytosol to result in the contraction of skeletal muscle. As the muscle fiber relaxes, calcium is
returned to the SR by sarco/endoplasmic reticulum calcium ATPase (SERCA) pumps (Nagelhout
& Elisha, 2018). Though the cause of MH is not fully understood, the widely accepted opinion is
that MH is a disorder of skeletal muscle function that is inherited and results in an abnormal
calcium regulation following the body’s exposure to a triggering agent (Nagelhout & Elisha,
2018). Acute episodes of MH are dependent upon four variables according to Miller (2015): “a
genetic predisposition, the absence of inhibiting factors, the presence of an anesthetic or
nonanesthetic trigger, and the presence of environmental factors that could potentiate the action
of one or more of the other three variables” (p. 1294).
Alterations in both the RYR1 and CACNA1S genes have been noted to be associated
with MH reactions, although the predominant genetic mutation responsible for MH involves the
RYR1 gene with a resultant defect in the ryanodine channel (Smith et al., 2018). The RYR1
receptor is the predominant receptor found in skeletal muscle that is necessary in the regulation
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of calcium. In patients that have an MH reaction, the accelerated release of calcium from the SR
into the cytosol progresses to a point that the SERCA pumps are unable to compensate; these
factors result in uninhibited muscular activity (Smith et al., 2018). Regardless of the genetic
component behind the disorder, an MH reaction is the result of an abnormally high calcium
release from the SR through the RYR1 channel causing dysregulation of excitation-contraction
coupling in the skeletal muscle (Hopkins et al., 2018). This alteration in calcium regulation
results in a rise in myoplasmic calcium levels that leads to the clinical manifestations that are
witnessed during an MH reaction. The increase in myoplasmic calcium levels leads to the
resultant sustained skeletal muscle contraction, as well as the loss in cellular membrane integrity
that causes hyperkalemia and rhabdomyolysis to be present (Schuster, 2013). The increased
activity of the SERCA pumps trying to correct calcium levels increases the cells’ need for ATP.
The result of these reactions is the production of heat, manifesting as the presence of
hyperthermia (Miller, 2015). Cell death ultimately occurs as a result of heat production and the
continual rise in calcium levels (Hopkins et al., 2018).
Morbidity and Mortality of MH
The mortality of MH was nearly 60% when it was first discovered, and because of the
development of protocols and the introduction of dantrolene into practice as a treatment
modality, the mortality rate has been reduced to less than 5% (Miller, 2015). Untreated MH
reactions will always be fatal due to cellular and end-organ complications (Hopkins et al., 2018).
The complications of MH can include acute renal failure, compartment syndrome, cardiac
dysfunction, disseminated intravascular coagulation (DIC), multiorgan failure, and death
(Nagelhout & Elisha, 2018).
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Contributing factors to increases in mortality rates can include a delay in the appropriate
treatment of the reaction and the failure to control the patient’s core temperature. Mortality rates
have been noted to increase 2.9 times per 2°C increase in maximum core temperature, and 1.6
times per 30-minute delay in the administration of dantrolene (Rosenberg, Sambuughin, Riazi, &
Dirksen, 2013). Mortality has also been noted to increase when the initial presentation of an MH
reaction occurs in an ambulatory surgery setting due to the potential lack in preparation and
education of personnel. For this reason, any facility that utilizes triggering agents should have
mock MH drills and formal education on a regular basis (Rosenberg et al., 2013).
In-Depth Epidemiology
The prevalence of MH in the pediatric patient population is about 1 in 10,000 general
anesthetics, which is greatly increased from the adult patient population prevalence rates of 1 in
50,000 general anesthetics (Rosenberg et al., 2013). The prevalence of MH in relatives that are
known carriers of an MH genetic mutation is 1 in 2,000 (Miller, 2015). MH reactions are thought
to affect males more than females, and are also more common in children under the age of 15.
The pediatric population accounts for 52.1% of all MH reactions (Miller, 2015).
The incidence of MH is not exactly known, but is estimated to be a complication that
occurs in the range of 1 in 3,000 to 1 in 50,000 general anesthesia cases (Nagelhout & Elisha,
2018). The incidence of an MH crisis is 1 in 4,500 general anesthetics when triggering agents are
utilized and decreases to 1 in 62,000 general anesthetics when triggering agents were not used
(Miller, 2015). The incidence of MH is also higher in the French, Scandinavian, and Japanese
populations, though every ethnicity may be affected (Mullins, 2017). Due to the genetic
component, clusters of MH susceptible patients exist in the states of Wisconsin, Nebraska, West
Virginia, and Michigan in the United States (Mullins, 2017).
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Genetic Considerations
MH is an inherited disorder through an autosomal dominant pattern with incomplete
penetrance, which accounts for for the relatives of carriers that do not develop MH susceptibility
(Nagelhout & Elisha, 2018). Each child of a parent with MH susceptibility has a 50% chance of
also being MH susceptible, and each grandchild of an MH susceptible adult has a 25% chance of
also being MH susceptible until the parents’ MH susceptibility status is known (Rosenberg et al.,
2013). Genetic or nongenetic factors may be responsible for the incomplete penetrance of this
genetic mutation, with a genetic factor being the degree of the anomaly noted in the gene
(Hopkins et al., 2018).
There have been six different forms of MH documented by researchers, with the most
common form being MHS1. This form of MH susceptibility occurs as the result of an alteration
in the RYR1 gene, which is responsible for 70% of the occurrences of the disorder (Rosenberg et
al., 2013). As previously mentioned, alterations in the RYR1 and CACNA1S genes have been
found to be associated with MH reactions, although the predominant genetic mutation
responsible for MH involves the RYR1 gene that leads to the subsequent defect in the ryanodine
channel (Smith et al., 2018).
Triggering Agents
Medications that are commonly given in the perioperative setting can be divided into
triggering agents and nontriggering agents. Triggering agents include all of the volatile
inhalational anesthetics (ether, halothane, enflurane, isoflurane, desflurane, and sevoflurane) and
the depolarizing muscle relaxant succinylcholine (Miller, 2015). Nondepolarizing muscle
relaxants, N2O, and other commonly used intraoperative medications are all considered
nontriggering anesthetics that are safe to use in known MH and possible MH susceptible
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patients. An episode of MH may be more pronounced in patients that receive both
succinylcholine and a volatile anesthetic (Miller, 2015). In contrast, an MH crisis can be delayed
in the presence of “mild hypothermia and the proadministration of barbiturates, tranquilizers,
propofol or nondepolarizing neuromuscular blockers” (Miller, 2015, p. 1294). In addition to
anesthetic triggering agents, there are also nonanesthetic triggers of MH that can include
environmental stressors. These stressors include, but are not limited to, heat exposure, exercise,
anoxia and/or excitement (Miller, 2015). The presence of a personal or family history of events
related to these nonanesthetic triggers should also be included in the preoperative patient
assessment.
Signs and Symptoms
The clinical manifestations of an MH crisis may include multiple clinical events and
changes in laboratory findings that can range in time of onset and severity. These clinical
manifestations may occur immediately after the induction of general anesthesia or could have a
delay in presentation. As aforementioned, the signs and symptoms are the result of the presence
of increased intracellular calcium concentrations and increased body metabolism. Early signs
that a patient may be having an MH event will include tachycardia, an increase in EtCO2 levels,
and masseter spasm (Nagelhout & Elisha, 2018). Tachypnea, skin mottling, generalized muscle
rigidity, profuse sweating, cardiac arrhythmias, and unstable blood pressure may also be present
during the early phase of an MH reaction. Late signs of an MH episode may include
hyperkalemia, a rapid increase in core body temperature, elevated CK levels, gross
myoglobinemia and myoglobinuria, cardiac arrest, and DIC (Miller, 2015).
Metabolic features. Due to the presence of sustained skeletal muscle activity in the
patient having an MH reaction, O2 consumption and CO2 production are severely increased as
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the body’s metabolic rate rises (Hopkins et al., 2018). These metabolic reactions result in the
increase in EtCO2 that is characteristic during the early phase of an MH reaction. An important
aspect to this rise in EtCO2 that is vital to the professionals’ differential diagnosis, is that it will
be refractory to an increase in minute ventilation. The peak level of EtCO2 and the time that it
takes to reach its peak are going to vary from case to case (Hopkins et al., 2018).
Cardiac symptoms are related to the adverse consequences of the ongoing
hypermetabolic state which includes acidosis, hyperthermia, and hyperkalemia. Tachycardias
develop in a compensatory effort of the heart to increase cardiac output as the O2 consumption of
the tissue continues to rise during the progression of the MH reaction (Hopkins et al., 2018).
Arrhythmias that may be seen during an MH reaction could include atrial and ventricular ectopy,
nodal tachycardias, bigeminal arrhythmias, and least common, ventricular tachycardia. The
presence of cardiac arrhythmias may be more common in the pediatric patient, making
electrocardiography an important monitoring tool in pediatric patients undergoing a general
anesthetic (Hopkins et al., 2018). Cardiac arrhythmias are also more common when using
halothane as an inhalational anesthetic gas (Chan et al., 2017).
In addition to the increase in EtCO2 and cardiac symptoms that are displayed, the
anesthesia professional may also notice an increase in the core temperature of the pediatric
patient. Pediatric patients, especially infants and neonates, are normally predisposed to a drop in
their core body temperature while in the operating room; this is due to a larger body surface area
and a reduced amount of subcutaneous and heat producing brown fats (Hines & Marschall,
2018). However, the sustained skeletal muscle contraction that occurs during an MH reaction as
a result of elevated calcium levels produces heat and a subsequent rise in core body temperature
(Hopkins et al., 2018). A significant temperature rise may be more evident as the reaction
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progresses, but will not be an early indicator of MH. If the MH reaction progresses to a point
where hyperthermia is a concern, a very rapid temperature increase will be noted by the
anesthesia practitioner, increasing the suspicion of MH in the differential diagnosis. When
hyperthermia is present, the patient’s temperature may be noted to precipitously rise at a rate of 1
to 2°C every five minutes (Mullins, 2017).
Muscle features. Masseter spasm is a common clinical manifestation that may be noted
during an MH reaction. Interestingly, masseter spasm can also be a side effect of succinylcholine
administration that is not related to an MH reaction. The differentiating factor anesthesia
professionals should consider when an MH reaction is suspected is the length of time that the
masseter spasm has been present. If the masseter spasm is occurring as a side effect of the
succinylcholine administration, it should subside in 60-90 seconds according to Hopkins et al.
(2018). Conversely, a masseter spasm occurring as a clinical manifestation of MH may last for
up to 5 minutes. If present, there is a 24-50% chance that a masseter spasm is related to an MH
event if it continues for longer than 2 minutes, and at this point alternate means of obtaining a
patent airway need to be explored (Hopkins et al., 2018). In addition to the spasm of the jaw
muscles, the presence of generalized muscle rigidity may also be noted after the administration
of a triggering agent to an MH susceptible patient (Hopkins et al., 2018). Due to the fact that
masseter spasm can be common after the administration of succinylcholine both as a side effect
and as a manifestation of MH, it should not be used as a sole diagnostic manifestation.
Rhabdomyolysis is another clinical manifestation that may be noted as an MH reaction
progresses. Continual muscle activity and heat production will result in the death of the muscle
cells, causing the release of potassium (Hopkins et al., 2018). As the muscle cells continue to die,
creatine kinase (CK) levels begin to rise and protein begins to be cleared in the urine, causing a
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dark-colored appearance. CK levels may continue to rise for up to 12-24 hours after the MH
reaction (Hopkins et al., 2018).
Laboratory findings. Laboratory findings that are consistent with an MH reaction will
include the presence of a mixed acidosis, hyperkalemia, elevated CK, elevated serum myoglobin,
and elevated urine myoglobin. Acidosis is a result of the increased CO2 production by skeletal
muscle cells and the alteration in the patient’s respiratory efforts. Metabolic features of acidosis
are the result of lactate production as the muscular metabolic rate is sustained at an abnormally
high level (Miller, 2015). As aforementioned, elevated potassium and CK levels, as well as the
signs of muscle breakdown are the result of rhabdomyolysis.
Diagnosis
The current gold standard for the diagnosis of MH include the halothane and caffeine
muscle contracture test or the caffeine halothane contracture test (Miller, 2015). To complete the
halothane and caffeine muscle contracture test, a biopsy of the quadriceps muscle is taken and a
series of studies are performed. As the study progresses, the muscle biopsy is assessed for the
threshold at which muscle tension is sustained. The caffeine halothane contracture test also takes
a muscle biopsy from one of a variety of sites and studies can then be undertaken. The patient
will be determined to be MH susceptible with a positive halothane or caffeine test and MH
negative when both of the test results are negative (Miller, 2015). The limitations to contracture
testing include that they must be completed at a qualified center, and they cannot be completed
on infant and pediatric patients under the age of 5 or patients that weigh less than 20 kg
(Rosenberg et al., 2013) (Smith et al., 2018). DNA testing that can be completed on patients of
any age is in the process of being developed, though it is likely that this testing may be
somewhat inaccurate in the diagnosis of MH susceptible patients.
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Differential diagnosis. Due to the broad spectrum of manifestations that may be seen
during the presentation of MH, there are a wide variety of conditions that need to be promptly
ruled out prior to the treatment of MH to ensure that the patient is receiving treatment for the
correct condition. It is important for the anesthesia professional to work through each differential
diagnosis thoroughly, but efficiently, to ensure a high-quality patient outcome. As an example,
tachycardia could be the result of hypoxia, hypercarbia, insufficient anesthetic depth, as a side
effect from an administered medication, or as the result of another hypermetabolic state.
Similarly, the increase in core body temperature could be due to a blood transfusion or drug
reaction, infection, neuroleptic malignant syndrome, serotonin syndrome, and other
hypermetabolic states (Hopkins et al., 2018). Masseter muscle rigidity may be the result of an
insufficient neuromuscular blockade, temporomandibular syndrome, neuroleptic malignant
syndrome, or myotonia. Also, as aforementioned, masseter spasm can be a side effect after the
administration of succinylcholine and should not be relied upon solely as a clinical indicator of
an MH reaction. After the administration of succinylcholine, it is common to have muscle
discomfort in the neck, shoulder and upper abdominal muscles that occurs as a result of muscle
fasciculations after its administration. Conversely, muscle rigidity and discomfort as the result of
an MH reaction may be more common in the calf muscles (Chan et al., 2017).
Syndromes that may develop a clinical presentation that is similar in presentation to that
of MH could include anaphylactic reactions, Freeman-Sheldon syndrome, malignant neuroleptic
syndrome, muscular dystrophies (i.e Duchenne and Becker), osteogenesis imperfecta, PraderWilli syndrome, thyroid storm, or Wolf-Hirschhorn syndrome (Miller, 2015). It is important to
note that because these reactions are not true MH reactions, these conditions and disorders will
not be responsive to standard MH treatments. If any of the early clinical manifestations
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mentioned above (i.e. tachycardia and/or an unexplained increase in EtCO2) are present after the
use of succinylcholine or volatile anesthetics, MH should be included in the differential
diagnosis and treatment should be initiated promptly if confirmed.
As can be seen, there are many conditions that must be considered and ruled out prior to
moving forward with the treatment of MH. An MH clinical grading scale was developed to aid
anesthesia professionals in the swift recognition and diagnosis of a possible MH event. This tool
aids the anesthesia professional in working through a differential diagnosis with rankings that
identify the probability of an MH event as a patient presents with clinical manifestations that
make the anesthesia practitioner question whether or not they may be having an MH reaction.
The clinical indicators including rigidity, muscle breakdown, respiratory acidosis, temperature
increase, cardiac involvement, and “other” are assigned points that can then applied to this
ranking tool (Chan et al., 2017). Based on the score that is achieved, the probability of an MH
reaction can be assumed.
Treatment
Acute treatment. Once a patient is suspected of having an MH reaction in the operating
room, the appropriate MH hotline should be notified for expert guidance in the treatment of an
MH crisis. The treatment of MH or suspected MH should be prompt and efficient for an optimal
patient outcome to be achieved. The triggering anesthetic should be discontinued immediately
and help should be summoned when MH is suspected. The surgeon should be made aware of the
concern of an MH reaction, and surgery should be stopped as soon as possible. If the surgery
needs to be continued, a nontriggering anesthetic should be utilized to continue with general
anesthesia. The patient should then be hyperventilated with 100% FiO2 with a fresh gas flow rate
of at least 10 L/min in an attempt to decrease EtCO2 levels. The breathing circuit should be
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changed and activated charcoal filters should be added to the inspiratory and expiratory limbs of
the circuit to remove residual volatile agent from the anesthesia machine (MHAUS, 2019).
Dantrolene is the only medication that has been shown to be effective in reversing the
MH reaction, making this a vital component of MH treatment protocol. Dantrolene works by
antagonizing the RYR1 receptor, ceasing the abnormal release of calcium from the SR of the
skeletal muscle cell (Nagelhout & Elisha, 2018). Dantrolene should be reconstituted with sterile
water and administered at a dose of 2.5 mg/kg intravenously every 5 to 10 minutes until the
initial symptoms of the MH episode are controlled (Miller, 2015). Because dantrolene is
preserved with mannitol, diuresis will be noted after its administration (Hall, 2001). This will aid
in the treatment of any rhabdomyolysis that may be present.
In the acute phase of an MH event, symptom management should be directed at the
treatment of hyperthermia, hyperkalemia, acidosis, oliguria, and cardiac arrhythmias (Mullins,
2017). If hyperthermia is present, the patient’s core body temperature should be actively cooled
to 38°C and should then continue to be monitored for subsequent improvement. Cardiac
arrhythmias should be treated as though they are being caused by hyperkalemia through the
administration of the treatments of calcium chloride, insulin and dextrose, and sodium
bicarbonate (MHAUS, 2019). Calcium channel blockers should not be used during an MH event
because of the risks of worsening hyperkalemia and severe hypotension (Rosenberg et al., 2013).
The anesthesia professional should ensure that urine output is at least 1 ml/kg/h through the
administration of diuretics and crystalloid fluids intravenously as indicated by the patient’s
presentation. Standard and invasive monitoring should be implemented as warranted by the
severity of the clinical manifestations during the MH event. When the patient is stable, they
should be transferred to a PACU or to an appropriate intensive care unit (ICU) for at least 24
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hours after the MH event to ensure the patient has stabilized. Signs that the patient is stabilizing
will include a decrease in EtCO2, a stable heart rate with a normal rhythm, and the resolution of
hyperthermia and muscular rigidity (MHAUS, 2019).
Prolonged treatment. Once the patient has been initially stabilized in the operating
room, the patient can then be moved to a PACU or an ICU for further monitoring and treatment
if indicated. Vital signs and laboratory studies including arterial blood gases, electrolytes, CK,
coagulation studies, and urine studies should be evaluated frequently to ensure effective
treatment has been provided. If clinical manifestations are refractory to the initial dose of
dantrolene, the medication can be repeated in the postoperative period based on the patient’s
clinical presentation every 10 to 15 minutes up to a maximum dose of 30 mg/kg. If the MHAUS
hotline had not already been notified, this should occur so appropriate treatment modalities can
continue to be implemented for the patient.
Recrudescence of MH may be possible after the initial event, even when the event has
been properly treated. This has been evidenced in 20 to 25% of MH episodes, and may be more
common in those that have a muscular body habitus, those that have a higher temperature
increase, or those that have a delay in onset of the MH reaction after induction (Smith et al.,
2018). For these reasons, it is recommended that patients that have had an MH reaction be
monitored in an appropriate ICU for a minimum of 36 hours (Rosenberg et al., 2013).
Anesthesia Considerations for MH Susceptible Pediatric Patients
Preoperative Considerations. Because many pediatric patients have not had a surgical
encounter prior to the scheduled procedure, the reliance on the family history that is obtained by
the anesthesia professional is of utmost importance. It is important to note that even if a pediatric
patient has had an uneventful prior exposure to a triggering agent, there is a chance that the
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patient may develop an MH reaction to a subsequent triggering anesthetic (Bassi & Smith, 2017).
Pediatric patients should be given oral anxiolytics in the preoperative area consisting of
midazolam and/or ketamine to aid in their transition to the intraoperative phase of care. Topical
anesthetics can also be applied during this phase of care to aid in the placement of a peripheral
intravenous line if it is needed promptly (Hines & Marschall, 2018).
Preoperative assessment. A thorough preoperative assessment should be completed for
each pediatric patient that will be undergoing general anesthesia that includes a family history of
complications related to general anesthesia. As aforementioned, because many pediatric patients
have not had a surgical encounter prior to the one that they are presenting for, obtaining an
accurate family history is of the utmost importance. If prior anesthetic records are available for
the child, they should be reviewed, keeping in mind that MH reactions may not occur with the
first exposure to a triggering anesthetic. Chan et al. (2017) stated that “On average, MH
susceptible patients have two uneventful anaesthetics before triggering with a third” (p. 712). A
family history of anesthesia related complications that would make anesthesia professionals
suspicious of an MH event could include an unanticipated death or intraoperative complication,
having a high fever, or the presence of muscle rigidity during or after surgery. There is also
supporting evidence that MH reactions can be precipitated by nonanesthetic triggers such as
extreme heat and rigorous exercise. Due to these factors, the personal and family history should
include an inquiry of the presence of cola-colored urine, high temperatures, or unanticipated
death after exposure to these nonanesthetic triggers.
Associated conditions. There are a group of neuromuscular diseases that have a higher
incidence of having a genetic and clinical link to MH susceptibility. Assessments for the
presence of these disorders should be included in the anesthesia professional’s preoperative
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assessment. These disorders include Central Core Disease, including the subsets of
multiminicore myopthay and minicore myopathy, as well as King-Denborough syndrome. It is
important to note that there is not an increased risk of MH in patients that have Duchenne or
Becker muscular dystrophy, neuroleptic malignant syndrome, myotonia congenita, and myotonic
dystrophy. Patients that have these conditions may develop a syndrome in relation to anesthetic
medications and gases that is similar in presentation to MH (Nagelhout & Elisha, 2018).
Preparation. If it is known that a patient with a history of MH or an MH susceptible
history will be presenting for surgery, a nontriggering anesthetic should be prescribed and the
appropriate precautions should be taken prior to the patient coming back to the operating room.
The anesthetic machine should be appropriately prepared to ensure that a triggering agent is not
inadvertently delivered to the pediatric patient during their intraoperative course. Preparatory
steps should include removal of anesthetic vaporizers from the machine; attaching a new,
appropriately-sized breathing circuit and breathing bag; placing a fresh CO2 absorbent; and
applying charcoal filters to ensure that the machine does not contain any residual volatile
anesthetic that could be delivered to the child to trigger an MH reaction (MHAUS, 2019).
MHAUS (2019) states that “These [charcoal] filters are effective in keeping gas concentration
below 5 ppm for up to 12 hours with fresh gas flows of at least 3 L/min.” If charcoal filters are
not readily available to the anesthesia professional, manufacturer recommendations should be
followed for flushing the anesthetic machine. This could mean flushing the anesthesia machine
for up to 20 minutes with 10 L/min of fresh gas. If charcoal filters are available to the facility,
the anesthetic machine should still be flushed, but the time is decreased to only 90 seconds
(MHAUS, 2019). The use of preoperative dantrolene for prophylaxis is not recommended when
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the patient is prescribed a nontriggering anesthetic, because the use of a nontriggering anesthetic
will not result in the occurrence of an MH reaction (Miller, 2015).
Intraoperative Considerations. The presentation of a fulminant MH crisis may manifest
as muscular rigidity after the administration of succinylcholine with induction followed by other
clinical manifestations that may include an unexplained increase in EtCO2, a decrease in SpO2,
or an increase in core body temperature. Because of this, it is the recommendation of MHAUS
that core temperature monitoring is used for each patient that will be undergoing general
anesthesia, especially when using a triggering anesthetic, to aid in the early detection of
temperature changes (Mullins, 2017). As should also be noted, anesthesia professionals often
avoid the use of succinylcholine in the pediatric population due to the unknown outcomes that
may occur related to undiagnosed MH susceptibility and muscular dystrophies of various types.
The clinical manifestations directly related to the presentation of MH can also be delayed
in onset, appearing after a normal induction and endotracheal intubation, but progressing to the
otherwise unexplained clinical manifestations that were described above (Miller, 2015). MH that
is delayed in onset can often be diagnosed promptly with the identification of an unexplained
increase in EtCO2, tachycardia, and muscle rigidity. Presentation of MH in the pediatric patient
can often be mistaken for a state of hypovolemia, allergic reactions, anticholinergic treatments,
and disturbances to the CNS (Smith, Tranovich, & Ebraheim, 2018). Specific to the pediatric
male, cardiac arrest due to hyperkalemia can be mistaken for MH. All of these factors complicate
the already difficult differential diagnosis even further.
Due to the concerns of potential complications related to the administration of triggering
agents in pediatric patients that may be unknown to be MH susceptible or that have undiagnosed
myotonic dystrophy, the use of total intravenous anesthesia (TIVA) for an anesthetic plan has
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been on the rise. There are many advantages to a TIVA in pediatric patients including decreased
airway reactivity, less incidence of emergence delirium, and neuroprotection (Lauder, 2014). The
disadvantages noted when a pediatric patient is prescribed a TIVA include the need for an
intravenous line prior to the initiation of their anesthetic, pain on injection of the medication, and
less predictable responses to the medications (Lauder, 2014).
Considerations for induction. It is ordinary to initiate general anesthesia with the use of
inhalational anesthetic agents in the pediatric patient population. It is after the patient has
reached an appropriate anesthetic depth that an intravenous line can then be placed for the child
so adjunct medications can be administered as needed. In the pediatric patient that has a personal
or familial history of MH, this is not possible, so the anesthetic management for this phase of
care changes. A nontriggering anesthetic should be prescribed, as presented in the case report
above. Preoperative oral midazolam in a dose of 0.5-0.7 mg/kg up to a maximum dose of 20 mg
can also be utilized to provide anxiolysis and some amnesia for the child prior to being brought
back to the operating room. N2O can then be utilized to provide further anxiolysis to the pediatric
patient for the placement of an intravenous catheter so a TIVA can be initiated. If the pediatric
patient is cooperative, or part of an age group that is able to appropriately follow directions,
EMLA cream can be applied and an intravenous line can be placed in the preoperative area so
general anesthesia can be initiated in a timelier manner upon the child’s arrival to the operating
room.
Considerations for maintenance. A pediatric TIVA can be completed with the use of
propofol, ketamine, or dexmedetomidine infusions with or without the use of adjunct
medications that are appropriately dosed for the pediatric patient. Examples of adjunct
medications that can be used may include fentanyl, morphine, hydromorphone, remifentanil, or
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ketamine. Also, the use of N2O can be an appropriate addition to the anesthetic plan when
indicated for the child. A propofol infusion will most commonly be utilized for a TIVA. For
pediatric patients in the age range of 3 to 11 years old, an initial bolus of 2-3 mg/kg can be used
for induction, followed by an infusion that will be titrated for an appropriate anesthetic depth as
determined by the procedure. A typical propofol infusion may be infused at a rate of 100-200
mcg/kg/min while being titrated for the desired effect (Jaffe, Schmiesing, & Golianu, 2014). The
concomitant use of a remifentanil infusion or the use of N2O can aid in achieving an appropriate
anesthetic depth for the surgical procedure that will be completed (Jaffe et al., 2014).
Another approach to the administration of a propofol infusion involves a stepwise fashion
to titrations that will be made. Lauder (2014) recommends an induction dose of 2.5 mg/kg of
propofol followed by an initial infusion rate of 15 mg/kg/h for 15 minutes. The infusion can then
be titrated down to 13 mg/kg/h for the next 15 minutes of the procedure, followed by 11 mg/kg/h
for 30-60 minutes, 10 mg/kg/h for the next 1-2 hours, and 9mg/kg/h for the remainder of the case
(p. 53). This infusion delivery model is described to maintain an appropriate plasma
concentration of propofol while not overmedicating the pediatric patient, which aids in the
expeditious emergence of the child. Lauder (2014) also notes that the requirement for propofol
will be increased in the pediatric patient less than three years of age and conversely may be
decreased when the anesthesia professional is utilizing adjunct medications such as fentanyl or
dexmedetomidine.
Although dexmedetomidine is not currently approved by the United States Food and
Drug Administration (FDA) for use in the pediatric patient population, there has been a rise in its
off-label use for TIVA and in the prevention of emergence delirium upon wakeup for children.
The properties of dexmedetomidine make the medication appealing for use in pediatric TIVAs,
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as respirations can be maintained while also providing a sedated state. A standard loading dose
can be utilized in the pediatric population at a dose of 1.0 mcg/kg over ten minutes prior to the
initiation of a continuous infusion. It is important to mention that one of the most common side
effects of dexmedetomidine is bradycardia, and therefore the bolus may be foregone by some
practitioners; decreased by other practitioners; or given over an even longer period of time by
others to help avoid this unwanted complication for the pediatric patient (Tobias, 2007). Tobias
(2007) describes the use of dexmedetomidine in an infusion dose of 0.2–0.7 mcg/kg/h with the
same pharmacokinetic profile as that which is displayed in the adult population, making its
actions predictable for the pediatric population. Another source described the successful use of
dexmedetomidine at an infusion rate of 0.5-2.0 mcg/kg/h without the use of a loading dose (Jaffe
et al., 2014). Due to the lack of approval from the FDA, the use of dexmedetomidine for
pediatric TIVAs should be assessed for risks and benefits by the anesthesia professional based on
each individual case. Anesthesia professionals should proceed with the use of dexmedetomidine,
based upon their assessment, utilizing vigilant monitoring for any subsequent adverse effects in
the pediatric patient.
If a nontriggering TIVA is going to be utilized in the pediatric patient, it may be prudent
for the anesthesia professional to implement the use of bispectral index (BIS) monitoring. This
monitoring modality may guide the anesthesia professional in providing a level of anesthesia that
both prevent the awareness of the child and also speeds their emergence when general anesthesia
is ceased (Rosenberg, Pollock, Schiemann, Bulger, & Stowell, 2015). It should be noted that BIS
monitoring may not be reliable in the pediatric patient less than five years old nor those that are
not paralyzed (Lerman & Johr, 2009).
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Considerations for emergence. Another concern in the pediatric patient population,
especially those presenting for a surgery involving the oropharynx, includes the potential for a
laryngospasm. It should be noted that there is evidence supporting the decreased incidence of
laryngospasm in pediatric patients that receive a TIVA for their general anesthetic in comparison
to an inhalational general anesthetic due to the decreased amount of airway irritation (Lauder,
2014). In the event of a laryngospasm, an intravenous or intramuscular dose of succinylcholine
may typically be utilized to break the spasm that is refractory to other initial treatments. Because
succinylcholine is a triggering agent, it cannot be used in this event for the MH susceptible
pediatric patient. In the event of a laryngospasm that cannot be broken with positive pressure
ventilation and other initial treatments, a dose of rocuronium 0.9-1.2 mg/kg should be used
(Orliaguet, Gall, Savoldelli, & Couloigner, 2012). If there is no intravenous access present in the
child, rocuronium is the only paralytic aside from succinylcholine that can be administered via
the intramuscular route for the treatment of a laryngospasm (Orliaguet et al., 2012).
Should the use of rocuronium be warranted for the child having a laryngospasm,
sugammadex or neostigmine may need to be used to reverse the resultant neuromuscular
blockade. Though there is still not FDA approval for its use in children, new research has shown
benefits for the use of sugammadex in infants, children and adolescents with various
neuromuscular diseases that need a full and adequate reversal prior to extubation (Tobias, 2017).
These studies have shown successful reversal and subsequent extubation after the administration
of the appropriate dose of sugammadex. Complications identified in early clinical trials of the
drug may include severe anaphylactic reactions and bradycardia after administration of
sugammadex (Tobias, 2017). Anesthesia professionals should be cognizant of the lack of FDA
approval for infants, children, and adolescents, again weighing risks and benefits for the pediatric
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patient prior to the administration of sugammadex. Neostigmine with the concomitant use of
glycopyrrolate will also give the patient an adequate reversal of neuromuscular blockade, with
the difference existing in the amount of time that it takes for the patient to reach total reversal
from their neuromuscular blockade (Tobias, 2017). Therefore, if a rapid reversal of
neuromuscular blockade is necessary, the anesthesia professional may choose to use
sugammadex as the reversal agent of choice for the child.
Postoperative Considerations. Pediatric patients are often discharged home in an
expedited manner due to the incidence of emergence delirium that is present upon their arrival to
PACU. The question can then be raised: Should a pediatric patient that has undergone a
nontriggering general anesthetic be monitored in the PACU for a longer period of time if they
have a personal or familial history of MH? Research completed by Barnes, et al. (2015)
concluded that pediatric patients that have received a nontriggering general anesthetic can safely
be discharged home in the same time frame as a patient that has no personal or familial history of
MH. Therefore, standard discharge protocols may be followed for the discharge of pediatrics
after their surgical procedure. Hines and Marschall (2018) recommended that pediatric patients
be monitored for a minimum of one hour, up to four hours, after a nontriggering anesthetic,
though if symptoms of MH have not occurred within one hour postoperatively, they are likely to
not occur. Pediatric patients can then be discharged home once the predetermined, facilityspecific discharge criteria have been met.
Local Anesthesia Considerations
Local anesthetics are known to be nontriggering anesthetic agents, so their use is
acceptable for patients that have a history of MH or are MH susceptible. The use of local
anesthesia may be beneficial to aid in the prevention of postoperative pain, but because the
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pediatric patient population is often uncooperative and unable to follow commands, regional
anesthesia may not be a good option for a sole anesthetic. However, topical anesthetics with the
addition of N2O may be useful in the placement of a peripheral intravenous line in the
preoperative or intraoperative phase of care (Hines & Marschall, 2018). This will increase
patient satisfaction with IV placement while also assuring that the general anesthetic can be
initiated promptly for the child.
Conclusions and Recommendations
In the previously discussed case, an in-depth preoperative assessment revealed the
concern of potential MH susceptibility in a pediatric patient presenting for an
adenotonsillectomy. The genetic considerations related to the disorder lead to the appropriate
management of a potentially MH susceptible pediatric patient. Through the implementation of
the appropriate preparatory steps, the use of a TIVA for general anesthesia, and the appropriate
postoperative management, the child had a safe and uneventful surgical encounter.
The genetic component of MH reinforces the fact that thorough family histories should
be taken for each pediatric patient that presents for a surgical procedure requiring general
anesthesia. Should the personal or family history reveal that the child presenting for a general
anesthetic is potentially MH susceptible, preparatory steps should be taken by anesthesia
practitioners to ensure that the patient will have a safe, but also effective, general anesthetic. The
anesthesia professional should take the steps aforementioned to prepare the anesthetic machine
for the patient, as well as develop an appropriately tailored anesthetic plan for the MH
susceptible pediatric patient.
If an MH susceptible pediatric patient presents for surgery, a TIVA can be performed
utilizing propofol or dexmedetomidine, along with other adjunct medications. This approach will
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ensure that an efficacious, multimodal general anesthetic is provided to the child. The addition of
BIS monitoring can be considered to be used to verify that an adequate depth of anesthesia is
being achieved. With the use of N2O for anxiolysis and/or EMLA cream, an intravenous line can
be successfully placed for the child that will be receiving a TIVA prior to coming back to the
operative suite to ensure the prompt initiation of the child’s general anesthetic.
Because of the implications that an unrecognized MH crisis can have, it is important for
the operating room staff and anesthesia professionals to be familiar with the presentation and
treatment of MH. Many sources suggest the implementation of annual MH mock drills to ensure
that staff are able to work as a team to find the resources that they will need if an MH crisis
would happen to occur in their operating room (Mullins, 2017). Mock drills make certain that
staff are aware of where to find the appropriate medications, protocols, and resources to provide
rapid treatment in a potentially fatal situation. If the clinical manifestations mentioned above are
noticed by the anesthesia professional, a quick, but thorough, differential diagnosis should be
commenced to ensure that the patient is treated properly according to the underlying condition.
The pediatric patient with a history of MH or who is potentially MH susceptible should
be monitored in the PACU for at least one hour after they have received a nontriggering
anesthetic. Generally, if symptoms of MH have not occurred within one hour of their general
anesthetic, they are likely to not occur. Patients should be discharged home only after the
anesthesia professional is certain that the pediatric patient has not suffered any complications
from their anesthetic, and once they have met the appropriate discharge criteria. If the anesthesia
professional verifies that the aforementioned steps are taken, the administration of a safe and
efficacious general anesthetic for the MH susceptible pediatric patient is achievable, as is the
swift recognition and treatment of an unexpected MH event.
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Malignant Hyperthermia
Malignant Hyperthermia Precautions
in the Pediatric Patient
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• An “uncommon, life-threatening, hypermetabolic disorder of
skeletal muscle”
• First case witnessed in 1920s
• Gold standard of diagnosis is the halothane and caffeine
muscle contracture test or the caffeine halothane contracture
test
– Cannot be completed in patient less than 5 years old or those that
weigh less than 20kg

• Clinical presentation mimics many other disease states,
complicating the differential diagnosis
(Nagelhout & Elisha, 2018; Miller, 2015; Hopkins et al., 2018;
Rosenberg et al., 2013)

Pathophysiology

Epidemiology
• Incidence is approximated to be 1:4,500 when using a
triggering anesthetic
• The pediatric patient population accounts for roughly 52.1%
of all MH reactions
• Males have a higher incidence than females
• Most common in patients under the age of 15
• Known MH clusters exist in the U.S.
• The prevalence in relatives that are known carriers is 1:2,000

Absence of
inhibiting
factors

Genetic
predisposition

Presence of a
trigger

MH

Presence of
potentiating
factors

(Nagelhout & Elisha, 2018; Miller, 2015; Hopkins et al., 2018;
Mullins, 2017)

Pathophysiology

• Has decreased from nearly 60% when MH was first discovered
to less than 5%
• Mortality increases:

Genetic Mutation

Ryanodine receptor malfunction

Unopposed calcium release from SR

Uninhibited skeletal muscle activity
Impaired cellular membrane integrity and
cell death
(Smith et al., 2018; Miller 2015)

Morbidity and Mortality

– 2.9 times per 2℃ increase in maximum core body temperature
– 1.6 times per 30-min delay in dantrolene administration
– In ambulatory surgery settings

• Complications include:
–
–
–
–
–

Acute renal failure
Compartment syndrome
Cardiac dysfunction
DIC
Multi-system organ failure

• Untreated MH reactions will be fatal 100% of the time
(Miller, 2015; Rosenberg, 2013)
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Case Information
• Surgical Procedure

• First case of the day
• A safe OR environment was able to be prepared:

– Tonsillectomy & Adenoidectomy

• Pertinent patient information
– 8 y/o Male
– 37.8kg; 58in

Preparatory Steps

- ASA 1
- No Known Allergies

• PMH: Recurrent Strep Tonsillitis; Lyme disease (2017); Left
arm fracture
• PSH: None
• Family history revealed MH in both the boy’s mother and
maternal grandmother
• Pre-op VS and ROS WNL
• Mallampati I; >3 FB; Full Neck ROM

–
–
–
–

Vaporizers were removed from the anesthesia machine
New pediatric-sized breathing circuit and breathing bag applied
New CO 2 absorbent placed
Charcoal filters to the inspiratory and expiratory limbs of the machine

– Machine flushed with high fresh gas flows for 90 seconds per
recommendations

• Dantrolene is the only medication known to reverse an MH
reaction
– Dantrolene dose was calculated to be 95 mg (2.5mg/kg)
– 5 vials reconstituted with 300 mL sterile water
(MHAUS, 2019)

Anesthetic Course
• Preoperatively

– +BBS, +EtCo2, Leak <20mmHg

• Ventilator Settings

– 20mg PO Midazolam

• 70/30 N2O/O2 used for 24g IV
placement

– PSV-PRO to achieve tidal
volumes of 4-6mL/kg

• Maintenance

• Induction

– Propofol infusion at
140mcg/kg/min

– 30mg Lidocaine
– 100mg Propofol
– 20mcg Fentanyl

Intraoperative Issues
• Surgical course was uneventful
• Vital signs, including temperature, remained WNL for the
duration of the surgery
• Fluid Administration
– 150mL lactated ringer’s

• Blood loss ~1mL

– 10mcg Fentanyl
– PONV Prophylaxis

• Technique
– 5.0 Oral RAE ETT
– Miller 2 blade used to establish
Grade 1 view

• 4mg Ondansetron
• 8mg Dexamethasone

• Initial temperature = 37℃

PACU
• Extubated drowsy, but awake, after thorough oral suctioning
prior to arrival in PACU
• 6L oxygen via simple facemask
• Immediate post-op temperature was 36.6℃
• No apparent anesthetic complications
• Vitals remained WNL
• Discharged home after 2 hour stay

Genetic Considerations
• There are six noted forms of MH
• The most widely accepted opinion is that MH is an inherited
disorder
• Autosomal dominant with incomplete penetrance
– Each child or sibling of a carrier has a 50% chance of being MH
susceptible

• RYR1 genetic mutation accounts for 70% of the occurrences of
the disorder

(Rosenberg et al., 2013; Nagelhout & Elisha, 2018)
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Triggering Agents
• Environmental Triggers

• Anesthetic Triggers

– Heat exposure
– Exercise

– Ether
– Halothane

– Anoxia
– Excitement

– Enflurane
– Isoflurane
– Desflurane
– Sevoflurane
– Succinylcholine

(Miller, 2015)

Intraoperative Considerations for the
Pediatric Patient
• Standard monitors, including [core] temperature
• Induction will look different from commonly used inhalational
induction
• Avoidance of succinylcholine for pediatric patients
• Utilization of TIVA
• If MH event is suspected based on clinical presentation,
treatment should not be delayed
– Have MH resources available
– Dantrolene 2.5 mg/kg is the only definitive treatment of MH
– Reconstitute with sterile water
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Preoperative Considerations for the
Pediatric Patient
• Thorough family history is very important
• Even if a pediatric patient has had an uneventful prior
exposure to a triggering agent, there is a chance that the
patient may develop an MH reaction to a subsequent
anesthetic
• Oral anxiolytics in the preoperative area
– i.e. Midazolam 0.5-0.7 mg/kg up to 20mg

• Non-triggering anesthetic should be prescribed
• Preparatory steps should be taken to make the OR safe for the
child’s anesthetic
(Bassi & Smith, 2017; Hines & Marschall, 2018; Chan et al., 2017)

TIVA for the Pediatric Patient
• Advantages
– Decreased airway reactivity
– Decreased incidence of emergence delirium
– Neuroprotection

• Disadvantages
– Need for IV prior to the initiation of the anesthetic
– Pain on injection of the medication
– Less predictable responses to the medications

• Due to larger volume of distribution, may need increased
induction doses

(Smith, Tranovich & Ebraheim, 2018)

(Lauder, 2015)

TIVA for the Pediatric Patient Cont.

TIVA for the Pediatric Patient Cont.

• Use of propofol, ketamine, or dexmedetomidine infusions as
wells as adjunct medications
• Propofol

• Dexmedetomidine

– Induction dose: 2.5 mg/kg (or 2-3 mg/kg)
– Infusion rate: 15 mg/kg/h for 15 minutes working down to a dose of
9 mg/kg/h to finish out the case
– OR Infusion rate: 100-200 mcg/kg/min
– +Remifentanil infusion: 0.1-0.2 mcg/kg/min
– +N20
– Increase dose in children less than 3 years old

– Not FDA approved for use in children
– *Loading dose: 1.0 mcg/kg over 10 min
– Infusion rate: 0.2-0.7 mcg/kg/h
– +Remifentanil infusion: 0.05-0.1 mcg/kg/min

• Ketamine
– Induction dose: 3-5 mg/kg
– Infusion: 0.2-1.5 mg/kg/h
– +Morphine infusion: 0.05 mg/kg/h
– Fentanyl or hydromorphone infusions are also options

• BIS monitoring
– Not reliable in patients less than 5 years old
(Lauder, 2014; Jaffe, 2015)

(Tobias, 2007; Jaffe 2015)
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Considerations for Emergence
• Laryngospasm
– Common complication/concern for the pediatric population
– Less common when using a TIVA
– Standard treatment includes the use of succinylcholine
– In lieu of succinylcholine, rocuronium can be used to treat
laryngospasm refractory to standard treatments
• Only other paralytic agent that can be given IM
• 0.9-1.2mg/kg (two to three times ED95)
• Reversal may be needed

(Lauder, 2015; Orilaguet et al., 2012; Tobias 2017)

Postoperative Considerations for the
Pediatric Patient
• Safe discharge home after appropriate Phase 1/Phase 2 stay
after receiving a non-triggering anesthetic
– Minimum 1 hour, possibly up to 4 hours
– Facility specific predetermined discharge criteria has been successfully
met

• MH symptoms that have not manifested after 1 hour are likely
to not occur

(Hines & Marschall, 2018; Barnes et al., 2015)

Case Review & Conclusions
• A thorough preoperative assessment prevented a potentially
fulminant MH crisis
• Preparation is key
• If MH is ever suspected, do not delay treatment
• Be aware of your resources and stay educated
• Successful management of MH susceptibility is attainable in
all phases of care
• Unrecognized and untreated MH reaction will be fatal 100% of
the time!
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